Stem-Cell Exhaustion and Intercellular Communication in Aging

Stem-cell exhaustion and altered intercellular communication are two interconnected hallmarks of aging. One concerns how tissue-specific stem and progenitor cells maintain and repair tissues. The other concerns how cells and organs exchange information through local signals, hormones, nerves, immune mediators, extracellular vesicles, and direct contact.

Neither hallmark establishes a generic “rejuvenation” treatment. A growth signal, stem-cell marker, mouse-regeneration result, or exosome product must be evaluated as a specific intervention rather than as proof that aging was reversed.

Short answer

• Stem-cell exhaustion does not mean every tissue simply runs out of stem cells. Aging can alter cell number, quiescence, self-renewal, differentiation, lineage balance, clonal composition, and the surrounding niche.
• Different tissues use different stem or progenitor populations. There is no single blood test that measures whole-body “stem-cell reserves.”
• Age-related clonal hematopoiesis shows why more stem-cell expansion is not automatically better: selected blood-forming clones can expand with age and associate with hematologic and cardiovascular risk.
• Altered intercellular communication can involve signals that are excessive, deficient, mistimed, mislocalized, or interpreted differently by aged target cells. It is not merely “weaker signaling.”
• Heterochronic parabiosis connected the circulations of young and old mice. It was not a transfusion trial and does not establish that young-donor plasma rejuvenates people.
• FDA reiterated in 2024 that it knows of no demonstrated clinical benefit from young-donor plasma for aging or memory loss and notes the risks of plasma transfusion.
• FDA also warns that many marketed stem-cell, stromal, cord-tissue, amniotic, placental, and exosome products are unapproved and have caused serious harms.
• Peptide effects on migration, growth factors, cytokines, or progenitor cells remain product-, tissue-, route-, and outcome-specific. “Activates stem cells” is not a clinical indication.

Two hallmarks connected by the tissue environment

A stem cell does not act alone. Its niche can include neighboring cells, extracellular matrix, nerves, blood vessels, immune cells, metabolites, oxygen, and circulating signals. An age-related repair defect may therefore reflect intrinsic changes in the stem cell, an altered niche, systemic signals, or several layers at once.

Stem-cell exhaustion is tissue-specific

Adult tissues differ substantially in turnover and regenerative organization:

• hematopoietic stem cells continually generate blood and immune lineages;
• intestinal stem cells support rapid epithelial renewal;
• skeletal-muscle satellite cells are recruited strongly after injury;
• skin and hair follicles contain several specialized progenitor compartments;
• neural stem and progenitor biology differs by brain region and life stage; and
• organs such as the heart have more limited regenerative capacity.

The word “exhaustion” compresses several possible changes:

• fewer functional stem cells;
• failure to remain appropriately quiescent;
• reduced self-renewal or engraftment;
• biased production of particular cell lineages;
• impaired differentiation;
• expansion of selected clones;
• altered metabolism or stress responses; and
• a niche that no longer provides the correct signals.

More proliferation is not a universal solution. Forcing cells out of quiescence can deplete some pools, increase replication stress, distort lineage production, or favor malignant growth.

Clonal hematopoiesis is not simple depletion

A 2014 study analyzed blood-derived DNA from more than 17,000 people. Detectable somatic mutations in genes recurrently altered in blood cancers became more common with age. These clones were associated with higher risks of hematologic cancer and mortality, with cardiovascular associations also reported.

This does not mean every clone becomes cancer or that one result diagnoses whole-body aging. It shows that an aging stem-cell compartment can expand selected lineages while becoming less balanced or more hazardous. A product claim promising “more stem cells” ignores clonality, lineage quality, and cancer surveillance.

A stem-cell marker is not restored tissue function

Cell number, CD markers, colony formation, organoids, engraftment, and recovery after experimental injury answer different questions. A laboratory study may show migration or proliferation without demonstrating correct differentiation, durable tissue integration, function, or safety.

Human regenerative evidence should identify:

1. the exact cell or product;
2. whether cells are autologous or donor-derived;
3. processing, expansion, purity, viability, and potency controls;
4. route and destination tissue;
5. clinically meaningful outcomes;
6. immune, infectious, thrombotic, and tumor risks; and
7. long-term follow-up.

Altered intercellular communication is not one pathway

Cells communicate over different distances and timescales:

• direct contact: Notch and other receptor–ligand systems;
• local signaling: paracrine growth factors, cytokines, chemokines, and extracellular-matrix cues;
• endocrine signaling: hormones and other circulating mediators;
• neural signaling: neurotransmitters and neuroendocrine pathways;
• immune communication: cell trafficking, antigen presentation, cytokines, and resolution signals; and
• extracellular vesicles: heterogeneous membrane-bound particles carrying proteins, lipids, metabolites, and nucleic acids.

Age-related change can occur at the sender, signal, transport system, receptor, downstream response, or feedback loop. A concentration measured in blood may not represent activity in a tissue, and returning one molecule to a younger average does not necessarily restore the network.

“Youthful levels” are not automatically therapeutic targets

Many signals have nonlinear or tissue-dependent effects. Growth-promoting pathways can support repair while also affecting glucose metabolism, edema, organ growth, or cancer risk. Inflammatory mediators can cause damage when persistent yet remain necessary for host defense. Hormone concentrations can change as compensation rather than as a primary defect.

An age association therefore needs causal and interventional evidence before it becomes a treatment target.

What parabiosis did—and did not—show

In a 2005 mouse study, researchers surgically joined young and old animals so they shared circulation. Exposure to the shared systemic environment changed Notch signaling and selected regenerative responses in aged muscle and liver progenitor cells.

That experiment showed that systemic context can influence aged progenitor behavior. It did not isolate one “young blood factor,” test a commercial plasma infusion, or establish safety and benefit in humans. Parabiosis exchanges cells, soluble factors, organs' responses, and blood volume continuously; a short plasma transfusion is not the same intervention.

FDA's young-plasma boundary

FDA's December 2024 update states that young-donor plasma is not approved to prevent normal aging or memory loss and that the agency is not aware of evidence demonstrating effectiveness for those uses. Plasma transfusion can cause allergic reactions, infectious transmission, respiratory complications, and other harms.

Listing a study on ClinicalTrials.gov or registering an establishment with FDA does not mean a young-plasma use is approved or legally marketed.

Exosomes and extracellular vesicles need exact identity

“Exosome” is often used commercially as though it were one ingredient. In biology, extracellular vesicles are heterogeneous particles whose size, formation route, cargo, source cell, culture conditions, isolation, storage, and target-cell effects can differ.

A preparation may contain multiple vesicle populations, proteins, lipids, nucleic acids, media components, or contaminants. Particle count alone does not establish identity, purity, potency, sterility, or a beneficial communication signal.

The Endocrine Society's scientific statement describes extracellular vesicles as an important emerging signaling system while emphasizing the field's measurement and translation challenges. FDA states that unapproved exosome products have been marketed with unsupported claims and reports serious adverse events.

Approved transplantation is not generic rejuvenation

Hematopoietic stem or progenitor cell transplantation is established for specific blood cancers, marrow-failure states, immune disorders, and other defined conditions. It involves conditioning, donor matching or autologous collection, specialized manufacturing and clinical care, and substantial risks. Its existence does not validate elective transplantation for normal aging.

FDA's consumer information identifies cord-blood hematopoietic progenitor products as an approved stem-cell category and warns that broadly marketed unapproved regenerative products have been associated with blindness, tumor formation, infections, neurologic events, unwanted immune reactions, and other harms.

Being derived from a person's own tissue does not by itself establish that a processed product is safe, effective, exempt from regulation, or appropriate for another route.

Where peptide and growth-factor claims fit

Peptides frequently mapped to regeneration or cell communication include GHK-Cu, thymosin beta-4 or TB-500, BPC-157, ARA-290 or cibinetide, Humanin, MOTS-c, and growth-hormone secretagogues. A pathway connection is only the beginning of evaluation.

• GHK-Cu: topical cosmetic and preclinical findings do not establish systemic stem-cell rejuvenation or injectable safety.
• Thymosin beta-4 and TB-500: they are not interchangeable molecules. Cell-migration or animal-repair findings cannot be relabeled as human stem-cell restoration.
• BPC-157: rodent injury models do not establish clinical regeneration, stem-cell renewal, or human safety.
• ARA-290/cibinetide: small human studies in specific neuropathy populations provide an investigational signal, not proof of whole-body repair.
• Humanin and MOTS-c: endogenous levels and preclinical signaling studies do not establish that administered products restore youthful intercellular communication.
• Growth-hormone secretagogues: increasing one endocrine signal does not recreate a younger signaling network and can introduce pathway-specific risks.

See the peptides and hallmarks evidence map, healing-peptides evidence guide, ARA-290 guide, and Humanin guide for compound-level evidence.

How to evaluate a regenerative product claim

A responsible path toward future product listings

For any stem-cell, exosome, plasma, peptide, or regenerative listing, preserve:

1. exact identity and biological source;
2. manufacturing and processing steps;
3. formulation, route, and storage;
4. studied cell type, tissue, species, and indication;
5. evidence level and clinically meaningful outcomes;
6. contamination, immunogenicity, tumor, thrombotic, and off-target risks;
7. FDA approval, investigational status, or other applicable category; and
8. lot-specific quality and chain-of-custody documentation.

Use the source directory for disclosed batch records, the sourcing policy for evaluation criteria, and the research methodology for evidence grading. Directory inclusion is not a recommendation to purchase or use a product.

References

1. López-Otín C, et al. Hallmarks of aging: an expanding universe. Cell. 2023. PubMed
2. Ermolaeva M, et al. Ageing and rejuvenation of tissue stem cells and their niches. Nature Reviews Molecular Cell Biology. 2022. PubMed
3. Jaiswal S, et al. Age-related clonal hematopoiesis associated with adverse outcomes. New England Journal of Medicine. 2014. PubMed
4. Conboy IM, et al. Rejuvenation of aged progenitor cells by exposure to a young systemic environment. Nature. 2005. PubMed
5. Salomon C, et al. Extracellular vesicles and their emerging roles as cellular messengers in endocrinology: an Endocrine Society scientific statement. Endocrine Reviews. 2022. PubMed
6. FDA. Update to important information about young-donor plasma infusions offered for profit
7. FDA. Important patient and consumer information about regenerative medicine therapies
8. FDA. Patient and consumer warning about risks from unapproved human-cell or tissue products

Continue the series

• DNA damage, telomeres, and epigenetics
• Cellular senescence, mitochondria, and nutrient sensing
• Proteostasis, autophagy, inflammation, and the aging microbiome
• Peptides and the hallmarks of aging: evidence map

Bottom line

Stem-cell exhaustion is a tissue- and niche-specific change, not a single depleted reservoir. Altered intercellular communication is a network problem, not a missing youth factor. Responsible educational and commerce pages should preserve exact product identity, tissue context, human outcomes, long-term safety, and regulatory status instead of translating mouse regeneration or signaling markers into rejuvenation claims.